Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1: Is it useful?

Laura Bergamino, Valeria Capra, Roberta Biancheri, Andrea Rossi, Angela Tacchella, Linda Ambrosini, Masashi Mizuguchi, Makiko Saitoh, Maria Grazia Marazzi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Acute Necrotizing Encephalopathy (ANE) is a rare disorder characterized by fever, seizures and rapid progression to coma after the onset of a viral infection. Most cases are sporadic, however the observation of multiple cases in the same family with recurrent episodes of ANE led to the identification of a genetic form of the disorder, called ANE1, and to the discover of the causative mutation in . RANBP2 gene. We report the first Italian child with ANE1 carrying the common c.1880C. >. T mutation in the . RANBP2 gene, who presented three episodes of acute encephalopathy in the first two years of life. The child showed a less severe clinical and neuroradiological course with respect to the previously reported patients. During the acute encephalopathy episodes he was treated with steroids and immunoglobulin. A very low steroid maintenance therapy was administered after the second episode until the onset of the third. Thirty days after the last episode he started monthly intravenous immunoglobulin that might be used for prevention of viral infections. At the moment he is still continuing a low steroid maintenance therapy and monthly IVIG. We could hypothesize that the less severe clinical presentation of the third episode might be correlated to the steroid treatment or that the patient grew older. Despite there is no evidence to support that ANE1 is an immune-mediated disease, immunomodulatory therapy might be considered in the management of ANE1 cases especially in early childhood, in which a fatal course has been frequently reported. Further studies will be necessary to define the clinical, immunological and genetic aspects, as well as the outcome of immunomodulatory therapy in patients with ANE1.

Original languageEnglish
Pages (from-to)384-391
Number of pages8
JournalBrain and Development
Volume34
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Immunomodulation
Brain Diseases
Steroids
Intravenous Immunoglobulins
Virus Diseases
Febrile Seizures
Mutation
Inborn Genetic Diseases
Immune System Diseases
Case Management
Coma
Genes
Immunoglobulins
Therapeutics
Observation
ran-binding protein 2

Keywords

  • Acute
  • Encephalopathy
  • Necrotizing
  • RANBP2
  • Recurrent
  • Steroid

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Pediatrics, Perinatology, and Child Health

Cite this

Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1 : Is it useful? / Bergamino, Laura; Capra, Valeria; Biancheri, Roberta; Rossi, Andrea; Tacchella, Angela; Ambrosini, Linda; Mizuguchi, Masashi; Saitoh, Makiko; Marazzi, Maria Grazia.

In: Brain and Development, Vol. 34, No. 5, 05.2012, p. 384-391.

Research output: Contribution to journalArticle

Bergamino, L, Capra, V, Biancheri, R, Rossi, A, Tacchella, A, Ambrosini, L, Mizuguchi, M, Saitoh, M & Marazzi, MG 2012, 'Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1: Is it useful?', Brain and Development, vol. 34, no. 5, pp. 384-391. https://doi.org/10.1016/j.braindev.2011.08.001
Bergamino, Laura ; Capra, Valeria ; Biancheri, Roberta ; Rossi, Andrea ; Tacchella, Angela ; Ambrosini, Linda ; Mizuguchi, Masashi ; Saitoh, Makiko ; Marazzi, Maria Grazia. / Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1 : Is it useful?. In: Brain and Development. 2012 ; Vol. 34, No. 5. pp. 384-391.
@article{0a22beba4bb74540b6f9ee25dce40859,
title = "Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1: Is it useful?",
abstract = "Acute Necrotizing Encephalopathy (ANE) is a rare disorder characterized by fever, seizures and rapid progression to coma after the onset of a viral infection. Most cases are sporadic, however the observation of multiple cases in the same family with recurrent episodes of ANE led to the identification of a genetic form of the disorder, called ANE1, and to the discover of the causative mutation in . RANBP2 gene. We report the first Italian child with ANE1 carrying the common c.1880C. >. T mutation in the . RANBP2 gene, who presented three episodes of acute encephalopathy in the first two years of life. The child showed a less severe clinical and neuroradiological course with respect to the previously reported patients. During the acute encephalopathy episodes he was treated with steroids and immunoglobulin. A very low steroid maintenance therapy was administered after the second episode until the onset of the third. Thirty days after the last episode he started monthly intravenous immunoglobulin that might be used for prevention of viral infections. At the moment he is still continuing a low steroid maintenance therapy and monthly IVIG. We could hypothesize that the less severe clinical presentation of the third episode might be correlated to the steroid treatment or that the patient grew older. Despite there is no evidence to support that ANE1 is an immune-mediated disease, immunomodulatory therapy might be considered in the management of ANE1 cases especially in early childhood, in which a fatal course has been frequently reported. Further studies will be necessary to define the clinical, immunological and genetic aspects, as well as the outcome of immunomodulatory therapy in patients with ANE1.",
keywords = "Acute, Encephalopathy, Necrotizing, RANBP2, Recurrent, Steroid",
author = "Laura Bergamino and Valeria Capra and Roberta Biancheri and Andrea Rossi and Angela Tacchella and Linda Ambrosini and Masashi Mizuguchi and Makiko Saitoh and Marazzi, {Maria Grazia}",
year = "2012",
month = "5",
doi = "10.1016/j.braindev.2011.08.001",
language = "English",
volume = "34",
pages = "384--391",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1

T2 - Is it useful?

AU - Bergamino, Laura

AU - Capra, Valeria

AU - Biancheri, Roberta

AU - Rossi, Andrea

AU - Tacchella, Angela

AU - Ambrosini, Linda

AU - Mizuguchi, Masashi

AU - Saitoh, Makiko

AU - Marazzi, Maria Grazia

PY - 2012/5

Y1 - 2012/5

N2 - Acute Necrotizing Encephalopathy (ANE) is a rare disorder characterized by fever, seizures and rapid progression to coma after the onset of a viral infection. Most cases are sporadic, however the observation of multiple cases in the same family with recurrent episodes of ANE led to the identification of a genetic form of the disorder, called ANE1, and to the discover of the causative mutation in . RANBP2 gene. We report the first Italian child with ANE1 carrying the common c.1880C. >. T mutation in the . RANBP2 gene, who presented three episodes of acute encephalopathy in the first two years of life. The child showed a less severe clinical and neuroradiological course with respect to the previously reported patients. During the acute encephalopathy episodes he was treated with steroids and immunoglobulin. A very low steroid maintenance therapy was administered after the second episode until the onset of the third. Thirty days after the last episode he started monthly intravenous immunoglobulin that might be used for prevention of viral infections. At the moment he is still continuing a low steroid maintenance therapy and monthly IVIG. We could hypothesize that the less severe clinical presentation of the third episode might be correlated to the steroid treatment or that the patient grew older. Despite there is no evidence to support that ANE1 is an immune-mediated disease, immunomodulatory therapy might be considered in the management of ANE1 cases especially in early childhood, in which a fatal course has been frequently reported. Further studies will be necessary to define the clinical, immunological and genetic aspects, as well as the outcome of immunomodulatory therapy in patients with ANE1.

AB - Acute Necrotizing Encephalopathy (ANE) is a rare disorder characterized by fever, seizures and rapid progression to coma after the onset of a viral infection. Most cases are sporadic, however the observation of multiple cases in the same family with recurrent episodes of ANE led to the identification of a genetic form of the disorder, called ANE1, and to the discover of the causative mutation in . RANBP2 gene. We report the first Italian child with ANE1 carrying the common c.1880C. >. T mutation in the . RANBP2 gene, who presented three episodes of acute encephalopathy in the first two years of life. The child showed a less severe clinical and neuroradiological course with respect to the previously reported patients. During the acute encephalopathy episodes he was treated with steroids and immunoglobulin. A very low steroid maintenance therapy was administered after the second episode until the onset of the third. Thirty days after the last episode he started monthly intravenous immunoglobulin that might be used for prevention of viral infections. At the moment he is still continuing a low steroid maintenance therapy and monthly IVIG. We could hypothesize that the less severe clinical presentation of the third episode might be correlated to the steroid treatment or that the patient grew older. Despite there is no evidence to support that ANE1 is an immune-mediated disease, immunomodulatory therapy might be considered in the management of ANE1 cases especially in early childhood, in which a fatal course has been frequently reported. Further studies will be necessary to define the clinical, immunological and genetic aspects, as well as the outcome of immunomodulatory therapy in patients with ANE1.

KW - Acute

KW - Encephalopathy

KW - Necrotizing

KW - RANBP2

KW - Recurrent

KW - Steroid

UR - http://www.scopus.com/inward/record.url?scp=84859888890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859888890&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2011.08.001

DO - 10.1016/j.braindev.2011.08.001

M3 - Article

C2 - 21945312

AN - SCOPUS:84859888890

VL - 34

SP - 384

EP - 391

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 5

ER -